Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Rating) insider Peter Soparkar acquired 21,925 shares of Adverum Biotechnologies stock in a transaction that occurred on Tuesday, April 19th. The shares were purchased at an average cost of $1.14 per share, with a total value of $24,994.50. Following the purchase, the insider now owns 280,556 shares of the company’s stock, valued at approximately $319,833.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
NASDAQ ADVM traded up $0.02 on Wednesday, reaching $1.14. 638,140 shares of the stock were exchanged, compared to its average volume of 1,168,514. Adverum Biotechnologies, Inc. has a one year low of $1.10 and a one year high of $10.33. The firm has a market capitalization of $112.58 million, a PE ratio of -0.76 and a beta of 1.23. The company’s 50-day simple moving average is $1.32 and its two-hundred day simple moving average is $1.68.
Adverum Biotechnologies (NASDAQ:ADVM – Get Rating) last released its quarterly earnings data on Tuesday, March 29th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.07. As a group, research analysts predict that Adverum Biotechnologies, Inc. will post -1.49 earnings per share for the current year.
A number of equities analysts have commented on ADVM shares. StockNews.com started coverage on shares of Adverum Biotechnologies in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research raised shares of Adverum Biotechnologies from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Monday, January 3rd. Finally, Chardan Capital reiterated a “neutral” rating on shares of Adverum Biotechnologies in a report on Monday, April 11th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Adverum Biotechnologies has a consensus rating of “Hold” and an average target price of $4.17.
Adverum Biotechnologies Company Profile (Get Rating)
Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.
- Get a free copy of the StockNews.com research report on Adverum Biotechnologies (ADVM)
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.